Blockade of metabotropic glutamate receptors inhibits cognition and neurodegeneration in an MPTP-induced Parkinson's disease rat model

Ming Hong Hsieh, Shih Chun Ho, Kuei Ying Yeh, Cornelius Rainer Pawlak, Hung Ming Chang, Ying Jui Ho, Te Jen Lai, Fu Ying Wu

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Hyperactivity of the glutamatergic system is involved in excitotoxicity and neurodegeneration in Parkinson's disease (PD). Metabotropic glutamate receptor subtype 5 (mGluR5) modulates glutamatergic transmission and thus has been proposed as a potential target for neuroprotective drugs. The aim of this study was to determine the effects of 2-methyl-6-(phenylethynyl)-pyridine (MPEP), an mGluR5 antagonist, on working memory, object recognition, and neurodegeneration in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD rat model. Male Wistar rats were stereotaxically injected with MPTP into the substantia nigra pars compacta (SNc). Starting 1 day after lesioning (day 1), the rats were treated daily with MPEP (2 mg/kg/day, i.p.) for 14 days and rats underwent a T-maze test on days 8-10 and an object recognition test on days 12-14. MPTP-lesioned rats showed impairments of working memory in the T-maze test and of recognition function in the object recognition test and both effects were prevented by MPEP treatment. Furthermore, MPTP lesion-induced dopaminergic degeneration in the nigrostriatal system, microglial activation in the SNc, and cell loss in the hippocampal CA1 area were all inhibited by MPEP treatment. These data provide support for a role of mGluR5s in the pathophysiology of PD and suggest that MPEP is a promising pharmacological tool for the development of new treatments for dementia associated with PD.

Original languageEnglish
Pages (from-to)64-71
Number of pages8
JournalPharmacology Biochemistry and Behavior
Volume102
Issue number1
DOIs
Publication statusPublished - Jul 2012
Externally publishedYes

Fingerprint

Metabotropic Glutamate Receptors
Cognition
Parkinson Disease
Rats
Metabotropic Glutamate 5 Receptor
Object recognition
Short-Term Memory
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Neuroprotective Agents
Data storage equipment
Dementia
Wistar Rats
Pharmacology
Chemical activation
Recognition (Psychology)
4-phenyl-1,2,3,6-tetrahydropyridine
pyridine
Pars Compacta
6-methyl-2-(phenylethynyl)pyridine

Keywords

  • Cognition
  • Dementia
  • Metabotropic glutamate receptor
  • MPEP
  • Parkinson's disease

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Pharmacology
  • Toxicology
  • Behavioral Neuroscience
  • Biological Psychiatry

Cite this

Blockade of metabotropic glutamate receptors inhibits cognition and neurodegeneration in an MPTP-induced Parkinson's disease rat model. / Hsieh, Ming Hong; Ho, Shih Chun; Yeh, Kuei Ying; Pawlak, Cornelius Rainer; Chang, Hung Ming; Ho, Ying Jui; Lai, Te Jen; Wu, Fu Ying.

In: Pharmacology Biochemistry and Behavior, Vol. 102, No. 1, 07.2012, p. 64-71.

Research output: Contribution to journalArticle

Hsieh, Ming Hong ; Ho, Shih Chun ; Yeh, Kuei Ying ; Pawlak, Cornelius Rainer ; Chang, Hung Ming ; Ho, Ying Jui ; Lai, Te Jen ; Wu, Fu Ying. / Blockade of metabotropic glutamate receptors inhibits cognition and neurodegeneration in an MPTP-induced Parkinson's disease rat model. In: Pharmacology Biochemistry and Behavior. 2012 ; Vol. 102, No. 1. pp. 64-71.
@article{4067431aec4b4a7a81787d06d7a119c9,
title = "Blockade of metabotropic glutamate receptors inhibits cognition and neurodegeneration in an MPTP-induced Parkinson's disease rat model",
abstract = "Hyperactivity of the glutamatergic system is involved in excitotoxicity and neurodegeneration in Parkinson's disease (PD). Metabotropic glutamate receptor subtype 5 (mGluR5) modulates glutamatergic transmission and thus has been proposed as a potential target for neuroprotective drugs. The aim of this study was to determine the effects of 2-methyl-6-(phenylethynyl)-pyridine (MPEP), an mGluR5 antagonist, on working memory, object recognition, and neurodegeneration in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD rat model. Male Wistar rats were stereotaxically injected with MPTP into the substantia nigra pars compacta (SNc). Starting 1 day after lesioning (day 1), the rats were treated daily with MPEP (2 mg/kg/day, i.p.) for 14 days and rats underwent a T-maze test on days 8-10 and an object recognition test on days 12-14. MPTP-lesioned rats showed impairments of working memory in the T-maze test and of recognition function in the object recognition test and both effects were prevented by MPEP treatment. Furthermore, MPTP lesion-induced dopaminergic degeneration in the nigrostriatal system, microglial activation in the SNc, and cell loss in the hippocampal CA1 area were all inhibited by MPEP treatment. These data provide support for a role of mGluR5s in the pathophysiology of PD and suggest that MPEP is a promising pharmacological tool for the development of new treatments for dementia associated with PD.",
keywords = "Cognition, Dementia, Metabotropic glutamate receptor, MPEP, Parkinson's disease",
author = "Hsieh, {Ming Hong} and Ho, {Shih Chun} and Yeh, {Kuei Ying} and Pawlak, {Cornelius Rainer} and Chang, {Hung Ming} and Ho, {Ying Jui} and Lai, {Te Jen} and Wu, {Fu Ying}",
year = "2012",
month = "7",
doi = "10.1016/j.pbb.2012.03.022",
language = "English",
volume = "102",
pages = "64--71",
journal = "Pharmacology, Biochemistry and Behavior",
issn = "0091-3057",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Blockade of metabotropic glutamate receptors inhibits cognition and neurodegeneration in an MPTP-induced Parkinson's disease rat model

AU - Hsieh, Ming Hong

AU - Ho, Shih Chun

AU - Yeh, Kuei Ying

AU - Pawlak, Cornelius Rainer

AU - Chang, Hung Ming

AU - Ho, Ying Jui

AU - Lai, Te Jen

AU - Wu, Fu Ying

PY - 2012/7

Y1 - 2012/7

N2 - Hyperactivity of the glutamatergic system is involved in excitotoxicity and neurodegeneration in Parkinson's disease (PD). Metabotropic glutamate receptor subtype 5 (mGluR5) modulates glutamatergic transmission and thus has been proposed as a potential target for neuroprotective drugs. The aim of this study was to determine the effects of 2-methyl-6-(phenylethynyl)-pyridine (MPEP), an mGluR5 antagonist, on working memory, object recognition, and neurodegeneration in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD rat model. Male Wistar rats were stereotaxically injected with MPTP into the substantia nigra pars compacta (SNc). Starting 1 day after lesioning (day 1), the rats were treated daily with MPEP (2 mg/kg/day, i.p.) for 14 days and rats underwent a T-maze test on days 8-10 and an object recognition test on days 12-14. MPTP-lesioned rats showed impairments of working memory in the T-maze test and of recognition function in the object recognition test and both effects were prevented by MPEP treatment. Furthermore, MPTP lesion-induced dopaminergic degeneration in the nigrostriatal system, microglial activation in the SNc, and cell loss in the hippocampal CA1 area were all inhibited by MPEP treatment. These data provide support for a role of mGluR5s in the pathophysiology of PD and suggest that MPEP is a promising pharmacological tool for the development of new treatments for dementia associated with PD.

AB - Hyperactivity of the glutamatergic system is involved in excitotoxicity and neurodegeneration in Parkinson's disease (PD). Metabotropic glutamate receptor subtype 5 (mGluR5) modulates glutamatergic transmission and thus has been proposed as a potential target for neuroprotective drugs. The aim of this study was to determine the effects of 2-methyl-6-(phenylethynyl)-pyridine (MPEP), an mGluR5 antagonist, on working memory, object recognition, and neurodegeneration in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD rat model. Male Wistar rats were stereotaxically injected with MPTP into the substantia nigra pars compacta (SNc). Starting 1 day after lesioning (day 1), the rats were treated daily with MPEP (2 mg/kg/day, i.p.) for 14 days and rats underwent a T-maze test on days 8-10 and an object recognition test on days 12-14. MPTP-lesioned rats showed impairments of working memory in the T-maze test and of recognition function in the object recognition test and both effects were prevented by MPEP treatment. Furthermore, MPTP lesion-induced dopaminergic degeneration in the nigrostriatal system, microglial activation in the SNc, and cell loss in the hippocampal CA1 area were all inhibited by MPEP treatment. These data provide support for a role of mGluR5s in the pathophysiology of PD and suggest that MPEP is a promising pharmacological tool for the development of new treatments for dementia associated with PD.

KW - Cognition

KW - Dementia

KW - Metabotropic glutamate receptor

KW - MPEP

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=84859804848&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859804848&partnerID=8YFLogxK

U2 - 10.1016/j.pbb.2012.03.022

DO - 10.1016/j.pbb.2012.03.022

M3 - Article

VL - 102

SP - 64

EP - 71

JO - Pharmacology, Biochemistry and Behavior

JF - Pharmacology, Biochemistry and Behavior

SN - 0091-3057

IS - 1

ER -